logo_new.jpg
ObsEva Reports First Quarter 2019 Financial Results
May 09, 2019 01:15 ET | ObsEva SA
  2019 Phase 3 Data Readouts on track for nolasiban in IVF and linzagolix in uterine fibroids;                 MAA submission for nolasiban IVF therapy targeted by year-end ...
logo_new.jpg
ObsEva SA Announces Initiation of Phase 3 EDELWEISS 2 and 3 Trials of Linzagolix for Endometriosis Associated Pain in U.S., Canada and Europe
May 09, 2019 01:00 ET | ObsEva SA
Geneva, Switzerland and Boston, MA – May 9, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel...
logo_new.jpg
ObsEva SA Announces that ObsEva’s Shareholders Approved all Board Proposals at its 2019 Annual General Meeting held on May 8, 2019
May 08, 2019 16:30 ET | ObsEva SA
Geneva, Switzerland and Boston, MA – May 8, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel...
logo_new.jpg
ObsEva SA Reports Consistent Long-Term Findings from Phase 2b EDELWEISS trial of Linzagolix for Endometriosis-Associated Pain
May 03, 2019 01:00 ET | ObsEva SA
                     Geneva, Switzerland and Boston, MA – May 3, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and...
logo_new.jpg
ObsEva SA to Hold First Quarter 2019 Financial Results and Business Update Call on May 9, 2019
May 01, 2019 01:00 ET | ObsEva SA
Geneva, Switzerland and Boston, MA –May 1, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization of novel...
logo_new.jpg
ObsEva SA Reports Further Infant Follow-up Data from IMPLANT2 Trial Echoing Favorable Safety Profile of Nolasiban in IVF
April 29, 2019 01:00 ET | ObsEva SA
Geneva, Switzerland and Boston, MA – April 29 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel...
logo_new.jpg
Publication of ObsEva SA Invitation to 2019 Annual General Meeting of Shareholders
March 29, 2019 02:00 ET | ObsEva SA
Geneva, Switzerland and Boston, MA – March 29, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel...
logo_new.jpg
ObsEva SA to Present OBE022 Clinical Data for Treatment of Pre-term labor (PTL) at the SRI 66th Annual Scientific Meeting, March 12 -16, 2019
March 13, 2019 02:00 ET | ObsEva SA
Geneva, Switzerland and Boston – March 13, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel...
logo_new.jpg
ObsEva Reports Fourth Quarter and Full Year 2018 Financial Results, Provides Business Update
March 05, 2019 01:00 ET | ObsEva SA
Major 2018 Accomplishments Driven by Positive Clinical Trial Results -Significant increase in rates of pregnancy and live birth (up to 35% increase in Day 5 ET) in Phase 3...
logo_new.jpg
ObsEva SA to Hold Fourth Quarter and Full Year 2018 Financial Results and Business Update Call on March 5, 2019
February 27, 2019 01:00 ET | ObsEva SA
Geneva, Switzerland and Boston, MA –February 27, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization of...